Fact checked byKristen Dowd

Read more

August 18, 2023
1 min read
Save

EMA accepts marketing authorization for delgocitinib for chronic hand eczema

Fact checked byKristen Dowd
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Key takeaways:

  • If approved, delgocitinib will be the first topical treatment for chronic hand eczema.
  • The application is supported by the DELTA phase 3 program.

The European Medicines Agency has validated the marketing authorization application for delgocitinib cream for moderate to severe chronic hand eczema treatment, LEO Pharma announced in a press release.

The acceptance of this marketing authorization for delgocitinib, an investigational product and topical pan-Janus kinase inhibitor for chronic hand eczema treatment in adults, marks the start of the formal review process.

Generic Breaking News infographic
The European Medicines Agency has validated the marketing authorization application for delgocitinib cream for moderate to severe chronic hand eczema treatment.

“We are delighted that delgocitinib cream has entered this first stage of the European regulatory process,” Kreesten Meldgaard Madsen, MD, PhD, chief development officer of LEO Pharma, said in the release. “If approved, it will be the first topical treatment specifically indicated and developed for moderate to severe [chronic hand eczema].”

The validation is based on results from the phase 3 program which includes DELTA 1 and DELTA 2 — two phase 3 trials that evaluated the safety and efficacy of delgocitinib cream vs. vehicle. Both trials met all primary and secondary endpoints, which has led to the start of a DELTA 3, an open-label, multi-site extension trial that is still ongoing. Interim data from DELTA 3 was also used to support this acceptance.